McKesson stock dips modestly as oncology deal and analyst targets set the tone

Published on 09/17/2026 at 20:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock trades at USD 889.78 on September 16, 2026, with analysts’ average price target at USD 980.73 and RBC Capital at USD 845. The company’s trailing revenue of USD 410.98 billion and net income of USD 4.59 billion highlight its scale.

Mitarbeiter sortieren unbeschriftete Pakete in einem großen Pharma-Logistiklager mit Regalen — Fotorealistisches Bild zeigt McKesson Corporation ISIN US58155Q1031 als Pharmagroßhändler in modernem Distributionslager mit vielen Mitarbeitern, Illustration mit AI erstellt.

McKesson Corporation stock (ISIN US58155Q1031) is changing hands at around USD 889.78 on the New York Stock Exchange as of September 16, 2026, about 1.1 percent below the prior close and roughly 9.3 percent under the average analyst price target of USD 980.73 per McKesson data on Yahoo Finance.

Analyst targets frame upside for McKesson stock

According to Yahoo Finance on September 16, 2026, McKesson stock trades at USD 889.78, down USD 9.78 or 1.09 percent from a previous close of USD 899.56, with a 52-week range between USD 687.68 and USD 999.00 and an intraday trading volume of 431,076 shares.

The same overview shows an analyst target spectrum with a low estimate of USD 845.00, an average of USD 980.73 and a high of USD 1,065.00 for McKesson stock, so the current price sits roughly 10.2 percent below the average target and 16.5 percent under the high target as of September 16, 2026.

RBC Capital and consensus views on valuation

As Yahoo Finance reports in its analyst insights dated September 14, 2026, RBC Capital reiterated a Sector Perform rating on McKesson stock and maintained its price target at USD 845.00, which now sits about 5 percent below the current market level.

In parallel, a recent analysis from StockStory highlights a consensus price target of USD 980.73 for McKesson with an implied return of 10.6 percent from a stock price of USD 886.80, underscoring that the broader analyst community still sees double-digit upside potential from current levels.

Scale and recent earnings underscore fundamentals

McKesson’s latest trailing fundamentals underline just how large the business has become in global healthcare distribution and services. According to the statistics section of Yahoo Finance, the company generated revenue of USD 410.98 billion over the trailing twelve months and earned net income attributable to common shareholders of USD 4.59 billion, implying a profit margin of 1.12 percent.

The earnings trends page on Yahoo Finance shows that in McKesson’s first quarter of fiscal year 2027, revenue reached USD 105.38 billion with earnings of USD 614 million, corresponding to a quarterly profit margin of about 0.58 percent, compared with the higher margin embedded in the trailing twelve-month figures.

Against this backdrop, the stock’s trailing price-to-earnings ratio of 23.87 and diluted earnings per share of USD 37.24 as stated in the same statistics overview suggest investors are willing to pay a premium for McKesson’s scale and cash generation relative to its thin operating margins.

Oncology growth and strategic deal as medium-term drivers

Recent coverage cited in the McKesson quote page on Yahoo Finance points to oncology as a key growth engine, with headlines noting McKesson raising its outlook and eyeing oncology growth alongside a precision medicine deal valued at about USD 2.25 billion, even though the underlying company release predates the current week.

In addition, the positive revenue trajectory is emphasized by StockStory, which notes that McKesson’s annual revenue growth of 14.5 percent over the last two years outpaced its sector and that share buybacks have helped earnings per share increase faster than revenue, reinforcing the investment case based on both growth and capital returns.

Risk spotlight: data breach incident adds operational scrutiny

While fundamentals and analyst views remain broadly supportive, operational risks have come into sharper focus after a cybersecurity incident involving McKesson’s systems. According to a timeline compiled by ZeroHour on September 17, 2026, the company disclosed that attackers accessed some third-party applications and stole data linked to a subset of customers in its oncology, multispecialty and medical-surgical business units during a four-day intrusion from August 21 to August 25.

For investors, that disclosure underscores that alongside the opportunity in precision medicine and oncology, McKesson must continue investing in security and governance to protect sensitive healthcare data, particularly as its role as a technology and services provider deepens.

McKesson stock price and market context

Per the latest real-time quote on Yahoo Finance, McKesson stock stands at USD 889.78 on the NYSE as of September 16, 2026, with the broader S&P 500 index at 7,513.47 points, meaning McKesson’s one-year return of 28.71 percent comfortably exceeds the S&P 500’s 13.76 percent over the same period.